You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The team will use the five-year funding to develop a liquid biopsy-based assay to select and prioritize liver cancer patients who need a liver transplant.
Cerevance, a drug discovery firm employing the transcriptome sequencing method, raised $45 million in Series B financing earlier this month.
The partners will specifically integrate Gilson's Trackman Connected digital bench tools and Qiagen's manual nucleic acid extraction kits.
The firm recently published a paper with its sibling company HiFiBio on antibody sequencing, but is looking to develop more applications.
Agilent, which co-led Mission Bio's 2018 $30 million Series B financing round, will comarket the Tapestri platform to cancer researchers in North America.
Ann Arbor, Michigan-based Celsee offers instruments and consumables for isolating, detecting, and analyzing single cells.
The partners will launch Zymo's DreamPrep NAP workstation to streamline DNA/RNA extraction for high-complexity testing labs running COVID-19 assays.
The alliance, led by Singapore-based startup Proteona, also includes several organizations from that city state as well as German research institutes.
The firm's single-cell T cell receptor profiling method was published this month as part of a study to develop reusable antigen reactivity screens.
A number of manufacturers say that the shortage of swabs and transport media for facilitating SARS-CoV-2 testing that clinicians are facing will soon abate.
The team has begun analyzing additional analytes in HER2-positive breast cancer patients and will present preliminary results at AACR's annual meeting in May.
The US Court of Appeals for the Federal Circuit sent the case, which had been thrown out in December 2018, back to the trial court.
The firms have entered into a strategic partnership to integrate their respective amplicon-based target enrichment technologies for use in NGS testing.
The Stanford University spinout claims it can get three times the nucleic acid yield as column- or magnetic bead-based methods, with less damage to the molecules.
Through a startup called FCS Technology, the team is hoping to market the platform for cancer research and, eventually, clinical diagnostic applications.
Under the terms of the non-exclusive agreement, the companies have made Diagenode's D-Plex library preparation products available on MGI's sequencing platforms.
Bioinformatics firm Next Gen Diagnostics will integrate Fluidigm's Juno microfluidic sample prep system into its workflow for pathogen whole-genome sequencing.
The product uses spin columns to extract high molecular weight DNA with an average length of 100 kb or more from animal and bacterial cells.
Boston-based NanoView aims to make its extracellular vesicle detection technology more widely available for research and biomarker discovery.
NuProbe's blocker displacement amplification technology selectively amplifies low-abundance sequence variants in a background of wildtype DNA.
The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.
New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.
In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.
Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.